RA Capital Management 13F holdings, Q4 2023
Holdings as of December 31, 2023 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 62 US equity positions worth $6.4bn in its Q4 2023 13F filing. The largest position was ASND at 19.9% of the reported book, followed by IMMUNOGEN INC and PCVX. Against the Q3 2023 filing, it opened 2 new positions, added to 7 and reduced 7 among the top 50 holdings.
What did RA Capital Management own in Q4 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2023 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S - ADR | Healthcare | 19.9% | $1.3bn | 10,107,400 | -6% | reduced |
| 2 | IMMUNOGEN INC | 11.0% | $704.2m | 23,750,601 | 78% | added | |
| 3 | PCVX VAXCYTE INC | Healthcare | 7.7% | $495.6m | 7,891,254 | 0% | held |
| 4 | LEGN LEGEND BIOTECH CORP-ADR | Healthcare | 5.9% | $376.9m | 6,264,707 | 0% | held |
| 5 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.8% | $245.0m | 5,330,412 | -6% | reduced |
| 6 | AEROVATE THERAPEUTICS INC | 2.9% | $187.0m | 8,263,982 | 0% | held | |
| 7 | INHIBRX INC | 2.8% | $179.5m | 4,724,207 | 0% | held | |
| 8 | CYMABAY THERAPEUTICS INC | 2.6% | $163.9m | 6,940,000 | 0% | held | |
| 9 | BIIB BIOGEN INC | Healthcare | 2.2% | $137.9m | 532,892 | 0% | held |
| 10 | RXST RXSIGHT INC | Healthcare | 2.1% | $137.3m | 3,404,285 | 12% | added |
| 11 | 89BIO INC | 2.0% | $127.5m | 11,416,948 | 0% | held | |
| 12 | VRNA VERONA PHARMA PLC - ADR | 2.0% | $125.6m | 6,317,990 | 0% | held | |
| 13 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 1.8% | $114.0m | 7,809,852 | 0% | held | |
| 14 | ANTX AN2 THERAPEUTICS INC | 1.8% | $113.7m | 5,551,295 | 0% | held | |
| 15 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.6% | $100.2m | 7,236,454 | 0% | held |
| 16 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.5% | $98.3m | 9,165,652 | 0% | held |
| 17 | GERN GERON CORP | Healthcare | 1.5% | $97.5m | 46,202,425 | 0% | held |
| 18 | ICOSAVAX INC | 1.5% | $94.0m | 5,963,565 | 0% | held | |
| 19 | ALPINE IMMUNE SCIENCES INC | 1.5% | $93.6m | 4,909,763 | 5% | added | |
| 20 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.4% | $91.9m | 18,202,009 | 6% | added |
| 21 | NEWAMSTERDAM PHARMA CO NV | 1.4% | $87.8m | 7,864,000 | -13% | reduced | |
| 22 | 4D MOLECULAR THERAPEUTICS IN | 1.3% | $84.3m | 4,163,211 | 0% | held | |
| 23 | EVH EVOLENT HEALTH INC - A | Healthcare | 1.3% | $84.2m | 2,549,132 | -7% | reduced |
| 24 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.2% | $79.6m | 1,000,000 | 0% | held |
| 25 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.2% | $78.4m | 11,609,704 | 0% | held |
| 26 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 1.0% | $62.1m | 6,809,404 | 0% | held |
| 27 | ABOS ACUMEN PHARMACEUTICALS INC | 0.9% | $57.3m | 14,932,063 | 0% | held | |
| 28 | PEPG PEPGEN INC | Healthcare | 0.9% | $55.3m | 8,131,952 | 0% | held |
| 29 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.9% | $55.3m | 1,977,901 | 0% | held |
| 30 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.8% | $51.8m | 9,459,678 | 0% | held |
| 31 | NKTX NKARTA INC | Healthcare | 0.8% | $51.5m | 7,805,129 | 0% | held |
| 32 | VOR VOR BIOPHARMA INC | 0.8% | $51.2m | 22,748,880 | 0% | held | |
| 33 | ITEOS THERAPEUTICS INC | 0.8% | $48.4m | 4,417,259 | 0% | held | |
| 34 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 0.7% | $47.3m | 204,500 | 0% | held |
| 35 | URGN UROGEN PHARMA LTD | Healthcare | 0.7% | $46.3m | 3,083,430 | 108% | added |
| 36 | MGNX MACROGENICS INC | Healthcare | 0.6% | $39.0m | 4,053,077 | 1085% | added |
| 37 | CLYM ELIEM THERAPEUTICS INC | 0.6% | $35.5m | 13,150,849 | 0% | held | |
| 38 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.5% | $32.7m | 18,472,503 | 0% | held |
| 39 | GHRS GH RESEARCH PLC | 0.5% | $32.4m | 5,587,333 | 0% | held | |
| 40 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.5% | $29.4m | 2,122,465 | 0% | held |
| 41 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.4% | $27.6m | 4,878,000 | – | new |
| 42 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.4% | $27.3m | 3,178,476 | 0% | held |
| 43 | HOWL WEREWOLF THERAPEUTICS INC | 0.4% | $23.7m | 6,144,881 | 0% | held | |
| 44 | ACRV ACRIVON THERAPEUTICS INC | 0.4% | $23.7m | 4,810,508 | 0% | held | |
| 45 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 0.4% | $23.2m | 1,281,000 | -27% | reduced |
| 46 | THIRD HARMONIC BIO INC | 0.3% | $22.3m | 2,033,056 | 111% | added | |
| 47 | AVIDITY BIOSCIENCES INC | 0.3% | $22.2m | 2,454,533 | -62% | reduced | |
| 48 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.3% | $21.0m | 3,426,286 | 0% | held |
| 49 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.3% | $19.8m | 486,832 | – | new |
| 50 | TNYA TENAYA THERAPEUTICS INC | 0.3% | $17.8m | 5,507,347 | -18% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.